2′,5′-Dideoxyadenosine 3′-di- and triphosphates were tested as inhibitors of brain adenylyl cyclases. With an IC50 ∼40 nM, 2′,5′-dideoxy-3′-ATP is the most potent non-protein synthetic regulator of adenylyl cyclases thus far described. Neither 2′,5′-dideoxy-3′-ADP nor 2′,5′-dideoxy-3′-ATP inhibited activity by competition with substrate, and the linear noncompetitive inhibition observed was consistent with interaction via a distinct domain. The availability of this ligand will permit the development of a variety of probes that will be extremely useful in investigating adenylyl cyclase structure and the role(s) that this class of compound may play in physiologically regulating cell function. 2′,5′-Dideoxyadenosine 3′-di- and triphosphates were tested as inhibitors of brain adenylyl cyclases. With an IC50 ∼40 nM, 2′,5′-dideoxy-3′-ATP is the most potent non-protein synthetic regulator of adenylyl cyclases thus far described. Neither 2′,5′-dideoxy-3′-ADP nor 2′,5′-dideoxy-3′-ATP inhibited activity by competition with substrate, and the linear noncompetitive inhibition observed was consistent with interaction via a distinct domain. The availability of this ligand will permit the development of a variety of probes that will be extremely useful in investigating adenylyl cyclase structure and the role(s) that this class of compound may play in physiologically regulating cell function.
No takes yet. Share an insight, caveat, or question.
Désaubry et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: